IRCT20210413050958N7 IRCT 2023-05-26 Mashhad University of Medical Sciences Effects of Acetyl-Leucine on Spinocerebellar ataxia The effects of N-Acetyl-L-Leucine on the improvement of symptoms in patients with Spinocerebellar ataxia 2023-06-22 anticipated 4 Complete https://irct.ir/trial/70303 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: Subjects are divided into one of two intervention/control groups using the random numbers prepared by a methodologist using www.sealedenvelope.com, so that who enrolled the trial can select a sealed envelope with random allocation sequence to the intervention or control group. An expert outside the research team blinds the drugs. The executive team register the subjects and assign them to the intervention. All volunteers, the executive team, and the statistical analyst will be blinded by the interventions, Blinding description: All volunteers, the executive team, and the statistical analyst will be blinded by the interventions. So that, the supplements containers were coded as A and B by a non-researcher person and remained confidential until data analysis. The placebos powders are similar to the supplements regarding the weight and color. 1-2 Spinocerebellar Ataxia. Intervention 1: Intervention group: Subjects in the intervention group receive N-Acetyl-L-Leucine sachet (daily intake of 2-4 gr depending on the subjects’ weight) for 4 weeks (n=2) and then after a 4-weeks wash-out period, they were crossed over to the alternate regimen. The participants take one sachet every day, which was contained in an unlabeled bottle. Supplements are from Hubei ipure Biotech co., ltd (Shenzhen, China). Intervention 2: Control group: The control group received a placebo sachet (daily consumption between 2 to 4 grams depending on the subject's weight) for 4 weeks (n=2) and then after a 4-weeks wash-out period, they were crossed over to the alternate regimen. Participants take a placebo every day orally in an unlabeled bottle. The placebo is prepared by from faculty of pharmacy (Mashhad, Iran) company. No - There is not a plan to make this available Justification or reason for not sharing IPD is Raw data will be shared upon a reasonable request from the corresponding author.